POM-V Prescription Required

Spasmipur 20 mg/ml Solution for Injection

Active ingredient: Hyoscine Butylbromide

Form

Injection

Species

Cattle Horses Pigs Sheep

Manufacturer

VetViva Richter GmbH

VMD MA No.

57446/4012

What it's used for

As an aid in procedures for which reduced peristaltic activity of the gastrointestinal tract or reduced contractions in the urinary tract are required.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Hyoscine Butylbromide

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Spasmipur 20 mg/ml Solution for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

As an aid in procedures for which reduced peristaltic activity of the gastrointestinal
tract or reduced contractions in the urinary tract are required.

Horses, cattle and pigs: 0.2 - 0.4 mg of hyoscine butylbromide/kg body weight by
intravenous injection (equivalent to 0.1 - 0.2 ml of the veterinary medicinal
product/10 kg body weight).
Sheep: 0.7 mg of hyoscine butylbromide/kg body weight by intravenous
injection (equivalent to 0.35 ml of the veterinary medicinal product/10 kg body
weight).
To reduce contractions of the smooth muscle in the gastrointestinal or urinary tract
(spasmolytic effect):
If necessary, treatment can be repeated once at 12 hours after initial administration
according to the veterinarian criteria.
Only in cases where intravenous injection is not possible, the veterinary medicinal
product may be administered intramuscularly at the higher dose specified for the
respective target species.
For clinical procedures (see indications for use):
Administer immediately before inactivity in the gastrointestinal or urinary
tract is required. For clinical procedures use intravenous administration
only.
A slow injection when using either the intravenous or the intramuscular route is
recommended.
AN: 00126/2024 and 00127/2024
To ensure a correct dosage, body weight should be determined as accurately as
possible and dosing devices or syringes with suitable graduations are to be used.
The rubber stopper can be punctured a maximum of 25 times.

Do not use in case of paralytic ileus, mechanical obstruction, or cardiac disorders.
Do not use in cases of hypersensitivity to the active substance or to any
of the excipients. Do not use in horses with glaucoma.
Do not use in horses less than 6 weeks of age.

Horses:
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
TachycardiaUndetermined frequency (cannot
be estimated from the available
data):
Colic
1
Due to inhibition of motility.
Cattle, sheep, pigs:
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Tachycardia
Reporting adverse events is important. It allows continuous safety monitoring of a
AN: 00126/2024 and 00127/2024
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the
national competent authority via the national reporting system. See the package
leaflet for respective contact details.

None.
AN: 00126/2024 and 00127/2024

Special precautions for safe use in the target species:
Horses should be monitored carefully following treatment.
The treatment is essentially symptomatic and an appropriate handling of the
underlying disorder is necessary.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals:
People with known hypersensitivity to hyoscine butylbromide or benzyl alcohol
should avoid contact with the veterinary medicinal product.
Accidental self-injection may result in cardiac and circulatory effects. Avoid
accidental self-injection. In case of accidental self-injection, seek medical advice
immediately and show the package leaflet or the label to the physician.
The veterinary medicinal product can cause skin and eye irritation. Avoid contact
with skin and eyes. In the case of contact with skin, wash with soap and water. If
irritation persists, seek medical advice. Wash hands after use.
If the veterinary medicinal product comes into contact with the eyes, rinse the eyes
immediately with plenty of water and seek medical attention if irritation persists.
Special precautions for the protection of the environment:
Not applicable.

This veterinary medicinal product may enhance the tachycardic effects of beta-
adrenergic drugs and may alter the effect of other drugs, such as digoxin.
The effects of hyoscine butylbromide may be potentiated by the concomitant use of
other anticholinergic drugs. Co-administration with other anticholinergic or
parasympatholytic drugs should be avoided.

This veterinary medicinal product does not require any special storage
conditions. After first opening the immediate packaging, do not store above
25°C.

Meat and offal:
Horses 3 days
Cattle 2 days
Sheep 18 days
Pigs 9 days
Milk:
Horses, Cattle and Sheep 12 hours

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.